Partial
Partially Aligned
Patient Risk:
Moderate
Summary
Several safety statements align with the label excerpts (HPA axis suppression, hyperglycemia, infection risk, blood pressure/weight changes, behavioral/mood/insomnia, GI effects, bone density/osteoporosis, cataracts/ocular effects, immunosuppression, vaccination guidance, live vaccine contraindication, and gradual tapering rather than abrupt stopping). However, multiple claims about dosing patterns (once-daily morning vs divided dosing) and specific use examples (e.g., autoimmune diseases like rheumatoid arthritis/lupus, inflammatory bowel disease, allergic reactions, asthma flare-ups, burst course length) are either not explicitly supported by the provided label excerpts or conflict with the delayed-release formulation administration instructions (should not be broken/divided).
Category Scores
Accurate Statements
Prednisone 5 mg is used to reduce inflammation.
Label mechanism indicates potent anti-inflammatory effects (Section 12.1).
Prednisone 5 mg is used to suppress the immune system.
Warnings: corticosteroids suppress the immune system and increase risk of infection (Section 5.2).
Prednisone should not be stopped abruptly after regular use, especially after more than a short course.
Dosage and Administration: recommended withdrawn gradually rather than abruptly after long-term therapy (Section 2.1).
The body’s own cortisol production can be suppressed by regular prednisone use.
Warnings: HPA axis suppression (Section 5.1).
Tapering prednisone is used to reduce the risk of adrenal insufficiency.
Warnings: reversible HPA axis suppression with potential corticosteroid insufficiency after withdrawal; gradual reduction (Section 5.1).
Long-term or repeated prednisone use can increase the risk of weight gain.
Adverse Reactions: common includes increased appetite and weight gain (Section 6).
Long-term or repeated prednisone use can increase the risk of high blood pressure.
Warnings: corticosteroids can cause elevation of blood pressure (Section 5.3) and Adverse Reactions include elevation in blood pressure (Section 6).
Long-term or repeated prednisone use can increase the risk of high blood sugar.
Warnings: hyperglycemia/monitor for hyperglycemia (Section 5.1) and Adverse Reactions include alteration in glucose tolerance (Section 6).
Long-term or repeated prednisone use can cause mood or sleep changes.
Warnings: behavioral and mood disturbances including insomnia/mood swings (Section 5.5) and Adverse Reactions include behavioral and mood changes and insomnia (Section 6).
Long-term or repeated prednisone use can increase the risk of infection.
Warnings: immunosuppression and increased risk of infection (Section 5.2).
Long-term or repeated prednisone use can cause stomach irritation.
Warnings: GI adverse risks/perforation/peptic ulcer risk (Section 5.4) and Adverse Reactions list GI ulcer/possible perforation and hemorrhage (Section 6).
Long-term or repeated prednisone use can increase the risk of osteoporosis.
Warnings: decrease in bone density leading to osteoporosis; monitor bone density (Section 5.6) and Adverse Reactions include osteoporosis (Section 6).
Long-term or repeated prednisone use can increase the risk of cataracts.
Warnings: prolonged use may produce posterior subcapsular cataracts (Section 5.7) and Adverse Reactions include posterior subcapsular cataracts (Section 6).
Long-term or repeated prednisone use can cause skin thinning.
No explicit support in the provided label excerpts.
Prednisone can raise blood sugar, especially in people with diabetes or prediabetes.
Warnings/precautions: hyperglycemia and monitoring; interactions require diabetes medicine dose adjustments (Sections 5.1 and 7.5). (Specific phrase 'diabetes or prediabetes' not explicitly quoted in provided excerpts.)
Prednisone can interact with blood thinners, and dose changes may be needed.
Drug Interactions: corticosteroids and warfarin; coagulation indices should be monitored frequently (Section 7.4).
Prednisone can interact with diabetes medicines by increasing blood sugar.
Drug Interactions: because corticosteroids may increase blood glucose, dosage adjustments of antidiabetic agents may be required (Section 7.5).
Prednisone can interact with nonsteroidal anti-inflammatory drugs (NSAIDs) by increasing stomach-bleeding risk.
Drug Interactions: concomitant use increases risk of gastrointestinal side effects; aspirin should be used cautiously (Section 7.13).
Live vaccines may be discouraged during steroid therapy.
Vaccination warning: administration of live or live attenuated vaccines contraindicated in patients receiving immunosuppressive doses of corticosteroids (Section 5.8).
Short 'burst' courses of prednisone can range from a few days to a couple of weeks depending on the condition.
No explicit support in the provided label excerpts.
Longer-term autoimmune or inflammatory management with prednisone often uses slow tapers.
Gradual withdrawal rather than abrupt stopping after long-term therapy; HPA-axis suppression risk supports gradual reduction (Section 2.1 and Section 5.1). (Specific 'often uses' wording not explicit.)
Prednisone commonly comes as oral tablets, including 5 mg.
Description indicates prednisone delayed-release tablets; dosage range includes starting dosage may vary from 5 to 60 mg/day (Sections 11/Description and 2.1).
Unsupported Statements
Prednisone 5 mg is a low-dose corticosteroid tablet.
Provided excerpts do not classify '5 mg' as low-dose.
Clinicians prescribe prednisone for allergic reactions.
Section 1 lists allergic conditions but the provided excerpt does not explicitly connect to 'allergic reactions' as phrased.
Clinicians prescribe prednisone for asthma flare-ups.
No explicit 'asthma' or 'asthma flare-ups' connection shown in provided excerpts.
Clinicians prescribe prednisone for autoimmune conditions such as rheumatoid arthritis or lupus.
Provided excerpt mentions a rheumatoid arthritis trial in Section 14, but does not explicitly state 'lupus' or describe autoimmune conditions generally in the exact terms used.
Clinicians prescribe prednisone for inflammatory bowel disease.
Although Section 1 includes GI diseases, the provided excerpts do not explicitly state inflammatory bowel disease.
For many inflammatory or immune conditions, prednisone is taken once daily.
No explicit once-daily dosing frequency in provided excerpts.
For many inflammatory or immune conditions, prednisone is often taken in the morning.
No explicit 'morning' timing instruction in provided excerpts.
A once-daily morning prednisone regimen is intended to better match the body’s natural cortisol rhythm.
No 'morning' regimen or 'cortisol rhythm matching' rationale is provided in the provided excerpts.
Some prednisone regimens use divided doses.
Label administration says prednisone delayed-release tablets should not be broken, divided, or chewed (Section 2.3), which undermines the idea of divided dosing of tablet formulation.
Some prednisone regimens use a taper.
Label supports gradual withdrawal after long-term therapy but does not explicitly state 'some regimens use a taper' as a general pattern in the provided excerpts.
Long-term or repeated prednisone use can cause stomach irritation.
GI risks are supported, but 'stomach irritation' is not an explicit label phrasing in the provided excerpts.
Even at 5 mg, the risks of prednisone side effects rise with duration and cumulative exposure.
No explicit statement in provided excerpts that 'even at 5 mg' risks rise with duration/cumulative exposure.
Patients may experience increased appetite and weight changes on 5 mg prednisone.
Adverse reactions list increased appetite and weight gain, but the provided excerpts do not tie these specifically to 'on 5 mg'.
Patients may experience trouble sleeping or jitteriness on 5 mg prednisone.
Insomnia is supported, but 'jitteriness' and 'on 5 mg' are not supported by provided excerpts.
Patients may experience mood changes such as irritability and anxiety on 5 mg prednisone.
Mood swings are supported, but the excerpt does not explicitly support 'irritability and anxiety' nor tie to 'on 5 mg'.
Patients may experience heartburn or stomach discomfort on 5 mg prednisone.
GI ulcer/perforation risk is supported, but 'heartburn' and 'on 5 mg' are not supported by provided excerpts.
Prednisone can interact with certain antifungals or other drugs that affect steroid metabolism.
Label excerpt provided mentions CYP3A4 inhibitors/inducers (ketoconazole and others), but the statement is too general; 'certain antifungals' is partially aligned yet not explicitly supported as phrased without naming examples beyond ketoconazole.
Long-term or repeated prednisone use can cause skin thinning.
No explicit support in provided label excerpts.
Contradictions
High
AI Statement
Some prednisone regimens use divided doses.
Label Reference
Section 2.3: prednisone delayed-release tablets should not be broken, divided, or chewed.
Important Omissions
Administration instruction: prednisone delayed-release tablets should be taken daily with food, and should not be broken, divided, or chewed.
Importance:
Moderate
Monitoring details during prolonged therapy (e.g., blood pressure, body weight, labs including 2-hour postprandial blood glucose and serum potassium, chest X-ray).
Importance:
Moderate
Contraindication specificity: hypersensitivity to prednisone or excipients (and rare anaphylaxis).
Importance:
Low
Safety Assessment
Potential Patient Risk:
Moderate
Main safety-relevant issue is the claim implying divided dosing of tablets, which conflicts with label instructions not to break/divide/chew the delayed-release tablets. Several other statements are generally consistent with label safety themes but are not always dosage-specific or timing-specific.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Conflicting administration guidance: 'divided doses' claim conflicts with 'should not be broken, divided, or chewed' for delayed-release tablets; additionally, multiple dosing-frequency/timing and condition-specific use examples are not explicitly supported by the provided excerpts.
Suggested Improvement
Remove or revise claims about divided dosing and any implied morning/once-daily regimen unless supported by the label text; align dosing/administration statements to: take daily with food and do not break/divide/chew; restrict condition-specific examples to those explicitly present in the provided label excerpts (Section 1).